These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 19761154)

  • 21. [Fabry disease (cardiac lysosomal storage disease) associated with heart failure].
    Takenaka T; Tei C
    Nihon Rinsho; 2007 May; 65 Suppl 5():460-4. PubMed ID: 17571419
    [No Abstract]   [Full Text] [Related]  

  • 22. The expanding clinical spectrum of Anderson-Fabry disease: a challenge to diagnosis in the novel era of enzyme replacement therapy.
    Hauser AC; Lorenz M; Sunder-Plassmann G
    J Intern Med; 2004 Jun; 255(6):629-36. PubMed ID: 15147526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical stability of Fabry disease in 54 months' enzyme replacement therapy--follow-up of the first Polish study].
    Bazan-Socha S; Miszalski-Jamka T; Petkow-Dimitrow P; Musiał J
    Pol Arch Med Wewn; 2007; 117(5-6):260-5. PubMed ID: 18030877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relief of gastrointestinal symptoms under enzyme replacement therapy [corrected] in patients with Fabry disease.
    Dehout F; Roland D; Treille de Granseigne S; Guillaume B; Van Maldergem L
    J Inherit Metab Dis; 2004; 27(4):499-505. PubMed ID: 15303007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enzyme reconstitution/replacement therapy for lysosomal storage diseases.
    Burrow TA; Hopkin RJ; Leslie ND; Tinkle BT; Grabowski GA
    Curr Opin Pediatr; 2007 Dec; 19(6):628-35. PubMed ID: 18025928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.
    Banikazemi M; Ullman T; Desnick RJ
    Mol Genet Metab; 2005 Aug; 85(4):255-9. PubMed ID: 15939645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early therapeutic intervention in females with Fabry disease?
    Hughes DA
    Acta Paediatr; 2008 Apr; 97(457):41-7. PubMed ID: 18339187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).
    Hoffmann B; Garcia de Lorenzo A; Mehta A; Beck M; Widmer U; Ricci R;
    J Med Genet; 2005 Mar; 42(3):247-52. PubMed ID: 15744039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.
    Lenders M; Brand E
    J Am Soc Nephrol; 2018 Sep; 29(9):2265-2278. PubMed ID: 30093456
    [No Abstract]   [Full Text] [Related]  

  • 30. Current enzyme replacement therapy for the treatment of lysosomal storage diseases.
    Lim-Melia ER; Kronn DF
    Pediatr Ann; 2009 Aug; 38(8):448-55. PubMed ID: 19725195
    [No Abstract]   [Full Text] [Related]  

  • 31. Non-specific gastrointestinal features: Could it be Fabry disease?
    Hilz MJ; Arbustini E; Dagna L; Gasbarrini A; Goizet C; Lacombe D; Liguori R; Manna R; Politei J; Spada M; Burlina A
    Dig Liver Dis; 2018 May; 50(5):429-437. PubMed ID: 29602572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Fabry disease : diagnosis and treatment].
    Üçeyler N; Sommer C
    Schmerz; 2012 Sep; 26(5):609-19. PubMed ID: 23052995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations.
    Oqvist B; Brenner BM; Oliveira JP; Ortiz A; Schaefer R; Svarstad E; Wanner C; Zhang K; Warnock DG
    Nephrol Dial Transplant; 2009 Jun; 24(6):1736-43. PubMed ID: 19293136
    [No Abstract]   [Full Text] [Related]  

  • 34. Predicting the Development of Anti-Drug Antibodies against Recombinant alpha-Galactosidase A in Male Patients with Classical Fabry Disease.
    van der Veen SJ; Vlietstra WJ; van Dussen L; van Kuilenburg ABP; Dijkgraaf MGW; Lenders M; Brand E; Wanner C; Hughes D; Elliott PM; Hollak CEM; Langeveld M
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32806627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey.
    Hoffmann B; Beck M; Sunder-Plassmann G; Borsini W; Ricci R; Mehta A;
    Clin J Pain; 2007; 23(6):535-42. PubMed ID: 17575495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.
    Mehta A; Ricci R; Widmer U; Dehout F; Garcia de Lorenzo A; Kampmann C; Linhart A; Sunder-Plassmann G; Ries M; Beck M
    Eur J Clin Invest; 2004 Mar; 34(3):236-42. PubMed ID: 15025684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Fabry disease: diagnostic due of substitutive enzyme-therapy].
    Barbey F; Widmer U; Burnier M; Lidove O
    Rev Med Suisse Romande; 2002 Sep; 122(9):449-53. PubMed ID: 12422475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enzyme replacement and beyond.
    Desnick RJ
    J Inherit Metab Dis; 2001 Apr; 24(2):251-65. PubMed ID: 11405344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.
    Bersano A; Lanfranconi S; Valcarenghi C; Bresolin N; Micieli G; Baron P
    Acta Neurol Scand; 2012 Aug; 126(2):77-97. PubMed ID: 22428782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paradoxical Response to Enzyme Replacement Therapy of Fabry Disease Cardiomyopathy.
    Frustaci A; Russo MA; Chimenti C
    Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27486136
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.